The U.S. National Cancer Institute awarded $10 million to support a multidisciplinary team led by Julio A. Aguirre-Ghiso to study breast cancer dormancy and relapse biology. The project is focused on understanding the processes that enable tumor cells to persist in a dormant state and later reactivate. For drug developers and translational researchers, dormancy programs are a high-priority area because relapse risk can persist after initial treatment, and current therapies rarely target the cellular states that drive late recurrence. The grant positions NCI-supported work to translate dormancy biology into actionable targets or biomarkers. The award signals sustained agency funding interest in recurrence prevention rather than only tumor shrinkage endpoints.